THOUSAND OAKS, Calif.–(BUSINESS WIRE) January 16, 2025 — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for…Original Article
Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo (tabelecleucel)
